Peter F. Lebowitz - Concepedia

Author

Peter F. Lebowitz

GlaxoSmithKline (United States)

Also Known As

P F Lebowitz, P. F. Lebowitz, P. Lebowitz, Peter F Lebowitz, Peter F. Lebowitz, Peter Lebowitz

Publications

7.3K

Citations

H-Index

Concepts

All Affiliations

GlaxoSmithKline (United States)The Wistar Institute University of Pennsylvania Sarah Cannon National Institutes of Health

About

Peter F. Lebowitz is an author at GlaxoSmithKline (United States) specializing in medicine, oncology, and tumor biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	14	2.9K
2	Health Sciences	2	2	169
3	Natural Sciences	2	2	472
4	Biochemistry	2	2	472
5	Biostatistics	1	1	65

Peter F. Lebowitz

Publications

Citations

H-Index

Page 1

	Year	Citations
Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations Keith T. Flaherty, J. Infante, Adil Daud, New England Journal of Medicine	2012	2.8K
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial Gerald S. Falchook, Georgina V. Long, Razelle Kurzrock, The Lancet Neuro-oncologyUntreated Brain MetastasesMedicineMelanomaPharmacotherapy	2012	928
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial Gerald S. Falchook, Karl D. Lewis, Jeffrey R. Infante, The Lancet Oncology MedicineMelanomaPharmacologyImmune Checkpoint InhibitorPharmacotherapy	2012	534
Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors. Richard Kefford, Hendrik‐Tobias Arkenau, Michael P. Brown, Journal of Clinical Oncology Phase I/ii StudyMut Braf MelanomaImmunotherapeuticsCancer BiologyTumor Biology	2010	274
Critical role of Rho in cell transformation by oncogenic Ras. George C. Prendergast, Roya Khosravi‐Far, Patricia A. Solski, PubMed	1995	253
Cell Growth Inhibition by Farnesyltransferase Inhibitors Is Mediated by Gain of Geranylgeranylated RhoB Wei Du, Peter F. Lebowitz, George C. Prendergast Molecular and Cellular Biology Cell ProliferationCell GrowthChemical BiologyTumor BiologyRas Prenylation	1999	250
Evidence that Farnesyltransferase Inhibitors Suppress Ras Transformation by Interfering with Rho Activity Peter F. Lebowitz, Joseph P. Davide, George C. Prendergast Molecular and Cellular Biology Stress Fiber FormationCell GrowthChemical BiologyTumor BiologyMolecular Pharmacology	1995	222
Farnesyltransferase Inhibitors Alter the Prenylation and Growth-stimulating Function of RhoB Peter F. Lebowitz, Patrick J. Casey, George C. Prendergast, Journal of Biological Chemistry	1997	215
Tumor Genetic Analyses of Patients with Metastatic Melanoma Treated with the BRAF Inhibitor Dabrafenib (GSK2118436) Katherine L. Nathanson, Anne‐Marie Martin, Bradley Wubbenhorst, Clinical Cancer Research	2013	183
Farnesyl transferase inhibitors induce apoptosis of Ras-transformed cells denied substratum attachment. Peter F. Lebowitz, Daitoku Sakamuro, George C. Prendergast PubMed Cancer ResearchOncogenic AgentRas-transformed CellsMedicineApoptosis	1997	182

Page 1